Details
Stereochemistry | RACEMIC |
Molecular Formula | C6H12O6 |
Molecular Weight | 180.1559 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC[C@@H](O)[C@@H](O)[C@@H](O)C(=O)CO
InChI
InChIKey=BJHIKXHVCXFQLS-PUFIMZNGSA-N
InChI=1S/C6H12O6/c7-1-3(9)5(11)6(12)4(10)2-8/h3,5-9,11-12H,1-2H2/t3-,5-,6+/m1/s1
Molecular Formula | C6H12O6 |
Molecular Weight | 180.1559 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
D-Psicose (akaD-allulose) is a low energy monosaccharide found throughout nature in small quantities. t is a c-3 epimer of D-fructose and has 50% the sweetness of sucrose. Possible health benefits include improved insulin resistance, antioxidant enhancement and formation, and hypoglycemic controls. The use US-FDA lists psicose as generally recognized as safe (GRAS) and has approved its use as a food additive in a wide variety of products. Psicose is not generally metabolized and does not raise blood sugar levels above baseline after consumption. In addition, to use as a low-calorie sweetener, psicose has also been formally investigated as a dietary supplement to control obesity and pre-diabetic insulin insensitivities. Furthermore, D-psicose has shown the ability to inhibit the proliferation of ovarian cancer cells in vitro.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Growth inhibitory effect of D-allose on human ovarian carcinoma cells in vitro. | 2005 Jul-Aug |
|
D-Psicose inhibits the expression of MCP-1 induced by high-glucose stimulation in HUVECs. | 2007 Jul 26 |
|
Influence of a rare sugar, d-Psicose, on the physicochemical and functional properties of an aerated food system containing egg albumen. | 2008 Jun 25 |
|
Hypoglycemic health benefits of D-psicose. | 2012 Feb 1 |
|
Rare sugar D-psicose protects pancreas β-islets and thus improves insulin resistance in OLETF rats. | 2012 Sep 7 |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02455934
Over 5 visits Healthy volunteers and volunteers with impaired fasting glucose consumed 1 of 5 beverages with 50 g sucrose and varying levels of D-psicose (0,2.5, 5, 7.5 and 10 g). Beverages were presented in a random order and the subject and investigator were blind to the composition of the beverage. Subjects maintained 24-hour dietary records prior to each visit and abstained from consuming any calories for 8 hours prior to the visit. Venous blood samples were collected prior to consuming the beverage and at 30, 60, 90, and 10 min after.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16080505
Human ovarian adenocarcinoma cells (OVACAT-3) were maintained at 37 deg-C under an atmosphere of 5% CO2 in RPMI 1640 medium and supplemented with 10% fetal calf serum, 10 micro-g/mL insulin, 100 IU/mL penicillin, and 100 micro-g/mL streptomycin. Cell growth assay was initiated when the OVCAR-3 cells were in the logarithmic growth phase. Cells were seeded onto a 96-well plate with medium and cultured for 24 hours. Culture medium was refreshed including 50 mM of D-psicose. After 1 - 5 days, 10 micro L of MTT solution was added to each well and the plates incubated another 4 hours at 37 deg-C. The dose-dependent effect was further investigated by adding different concentrations of D-psicose (1, 5, 10, 20, 50 mM). The final MTT assay was performed after 1- 3 days. The inhibitory effect of D-allose on cancer cell proliferation was shown from day 1 and became more significant at day 5, in contrast to untreated cells. Furthermore, studies on the concentration effect of
D-allose indicated that D-allose inhibits cells proliferation
in a dose-dependent manner
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:17:14 GMT 2023
by
admin
on
Sat Dec 16 11:17:14 GMT 2023
|
Record UNII |
KRF88IOA7T
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
KRF88IOA7T
Created by
admin on Sat Dec 16 11:17:14 GMT 2023 , Edited by admin on Sat Dec 16 11:17:14 GMT 2023
|
PRIMARY | |||
|
23140-52-5
Created by
admin on Sat Dec 16 11:17:14 GMT 2023 , Edited by admin on Sat Dec 16 11:17:14 GMT 2023
|
PRIMARY | |||
|
33951
Created by
admin on Sat Dec 16 11:17:14 GMT 2023 , Edited by admin on Sat Dec 16 11:17:14 GMT 2023
|
PRIMARY | |||
|
DB15087
Created by
admin on Sat Dec 16 11:17:14 GMT 2023 , Edited by admin on Sat Dec 16 11:17:14 GMT 2023
|
PRIMARY | |||
|
90008
Created by
admin on Sat Dec 16 11:17:14 GMT 2023 , Edited by admin on Sat Dec 16 11:17:14 GMT 2023
|
PRIMARY | |||
|
1013115
Created by
admin on Sat Dec 16 11:17:14 GMT 2023 , Edited by admin on Sat Dec 16 11:17:14 GMT 2023
|
PRIMARY | |||
|
DTXSID901018792
Created by
admin on Sat Dec 16 11:17:14 GMT 2023 , Edited by admin on Sat Dec 16 11:17:14 GMT 2023
|
PRIMARY | |||
|
498
Created by
admin on Sat Dec 16 11:17:14 GMT 2023 , Edited by admin on Sat Dec 16 11:17:14 GMT 2023
|
PRIMARY | |||
|
Psicose
Created by
admin on Sat Dec 16 11:17:14 GMT 2023 , Edited by admin on Sat Dec 16 11:17:14 GMT 2023
|
PRIMARY |